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Abstract
Background: The neutrophil-to-lymphocyte ratio (NLR) is a marker of systemic inflammation that informs clinical
decisions regarding recurrence and overall survival in most epithelial cancers. Radiotherapy for head and neck
cancer leads to mucositis in almost all patients and severe radiation-mucositis affects their quality of life (QOL).
However, little is known about the NLR for severe mucositis. Therefore, this study aimed to show the association
between the NLR and severe radiation-induced mucositis in hypopharyngeal or laryngeal cancer patients.
Methods: In this retrospective study, we determined the incidence of grade 3 mucositis in 99 patients who were
receiving definitive radiotherapy or chemoradiotherapy (CRT) for hypopharyngeal or laryngeal cancer. We
performed univariate and multivariate logistic regression analyses to investigate the characteristics of grade 3
mucositis. Kaplan–Meier curves and log-rank tests were used to evaluate the occurrence of grade 3 mucositis
between two groups with high (NLR > 5) or low (NLR < 5) systemic inflammation.
Results: The incidence of grade 3 mucositis was 39%. Univariate logistic regression analysis showed that the NLR
(Odd ratio [OR] = 1.09; 95% confidence interval [CI] = 1.02–1.16; p = 0.016) and smoking (OR = 1.02; 95% CI = 1.00–
1.03; p = 0.048) were significantly associated with grade 3 mucositis. Multivariate logistic regression analysis showed
that the NLR was independently associated with grade 3 mucositis (OR = 1.09; 95% CI = 1.01–1.17; p = 0.021).
Kaplan–Meier curves also showed that patients with higher NLR (NLR > 5) prior to radiotherapy developed grade 3
mucositis more frequently than those with lower NLR during radiotherapy (p = 0.045).
Conclusion: This study suggests that a higher NLR is a risk factor and predictor of severe radiation-induced
mucositis in hypopharyngeal or laryngeal cancer patients.
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Background
Radiotherapy is a standard therapy for head and neck
cancer. Radiotherapy, unlike surgery, has the advantage
of organ preservation, however, mucositis usually de-
velops as acute toxicity. Moreover, concomitant CRT in-
duces more severe mucositis than radiotherapy alone [1,
2]. No preventive or curative treatment for radiation-
induced mucositis has been established, and thus opioid-
based pain control programs are generally conducted for
palliative care purposes [3].
Radiation-induced oral mucositis may lead to infectious
diseases: oral candidiasis [4] and aspiration pneumonia
[5]. The National Comprehensive Cancer Network Guide-
lines® recommend oral management of radiotherapy for
head and neck cancers [6]. Severe oral mucositis affects
not only the QOL of patients but also the completion of
radiotherapy. Opioid-based pain control programs some-
times cannot inhibit severe oral mucositis and there are
opioid-related adverse events; thus, studies on topical
management have been conducted. A systematic review
showed that the recommendation for benzydamine
mouthwash to prevent radiotherapy-induced mucositis
remained unchanged [7], however, since the use of this
drug is not permitted in Japan, it cannot be used.
Many cancers arise from sites of infection, chronic irri-
tation and inflammation. The tumor microenvironment,
which is largely orchestrated by inflammatory cells, is an
indispensable participant in the neoplastic process, fos-
tering proliferation, survival and migration [8]. New bio-
markers of inflammatory response from serum are
prognostic in many solid cancers. Elevated C-reactive
protein and neutrophil-to-lymphocyte ratio (NLR) were
associated with more advanced disease and poorer prog-
nosis in oral cavity squamous cell carcinoma patients
[9]. Moreover, head and neck squamous cell carcinoma
cancer patients with NLR > 5 were predicted to have
shorter overall survival [10].
A retrospective study showed that male sex, oropharyngeal
cancer, low concentration of hemoglobin, low leukocyte or
lymphocyte counts, concurrent cisplatin or cetuximab, and
oral feeding were significantly associated with a higher inci-
dence of severe oral mucositis in 326 patients with oral or
oropharyngeal cancer [1]. The NLR is related to the inflam-
matory system, thus, high NLR may affect the severity of
radiation-induced mucositis; however, this relationship has
not been investigated yet. Therefore, this study was designed
to describe the association between the NLR and the inci-
dence of grade 3 mucositis.
Methods
Setting and design
We retrospectively reviewed the medical records of 99
patients who received oral management in association
with radiotherapy for pharyngeal or laryngeal cancer at
the Oral Management Center in Nagasaki University
Hospital (Nagasaki, Japan) between July 2011 and June
2020. The eligibility criteria included patients who had
pathologically confirmed primary mucosal squamous cell
carcinoma and underwent definitive radiotherapy or
CRT. Patients’ oral cavities were partially included in the
irradiated area.
The trial was conducted in accordance with the Declar-
ation of Helsinki (as revised in 2013). The study was ap-
proved by the Institutional Review Board (IRB) of Nagasaki
University Hospital (approval number: 20122114). The need
for informed consent was waived by the Nagasaki University
Hospital Clinical Research Ethics Committee because of the
retrospective nature of the study. Moreover, the research
plan was published on the homepage of the participating
hospitals according to the instructions of the IRB in accord-
ance with the guaranteed opt-out opportunity.
Outcome
The severity of radiation-induced pharyngeal or laryn-
geal mucositis was graded according to the National
Cancer Institute Common Terminology Criteria for Ad-
verse Events Version 5.0 (CTC v5.0) [11]. The nearest
match to the grade specified in the CTC v5.0 was used.
The highest grade of the severity of the mucositis during
radiotherapy was recorded.
The severity of pharyngeal mucositis was as follows:
grade 1, endoscopic findings only, minimal symptoms
with normal oral intake, mild pain but analgesics not in-
dicated; grade 2, moderate pain, analgesics indicated, al-
tered oral intake, limiting instrumental activities of daily
living (ADL); grade 3, severe pain, unable to adequately
aliment or hydrate orally, limiting self-care ADL; grade
4, life-threatening consequences, urgent intervention in-
dicated; and grade 5, death. The severity of laryngeal
mucositis was as follows: grade 1, endoscopic findings
only, mild discomfort with normal intake; grade 2, mod-
erate pain, analgesics indicated, altered oral intake, lim-
ited instrumental automated ADL; grade 3, severe pain,
severely altered eating/swallowing, medical intervention
indicated; grade 4, life-threatening airway compromise,
urgent intervention indicated (e.g., tracheotomy or in-
tubation); and grade 5, death.
Oral management associated with radiotherapy
All the patients received oral management prior to the
commencement of radiotherapy [12]. Oral and dental
evaluations, including panoramic X-ray examinations,
were performed immediately after the introduction of
doctors and infected teeth were extracted to prevent
osteoradionecrosis. During radiotherapy, the teeth in
dentulous patients were covered by spacers to prevent
scatter radiation, particularly from metallic restorations
and enamel surfaces exposed to the oral mucosa. A
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dental hygienist administered professional oral care at
least once a week. Oral care methods included dental
plaque removal via professional mechanical tooth clean-
ing methods and gentle removal of mucosal debris with
a water-drenched sponge to keep the oral cavity as clean
as possible. Oral rinsing with 4% sodium gualenate hy-
drate solution was prescribed at least four times daily.
Oral care continued until the end of the radiotherapy
treatment or hospital discharge.
Characteristics
The following demographic and clinical characteris-
tics were collected from the medical records: demo-
graphic factors (age, sex, body mass index [BMI],
history of smoking in pack-years, Eastern Coopera-
tive Oncology Group performance status [ECOG PS],
and diabetes mellitus); tumor-related factors (primary
tumor location and stage); treatment-related factors
(concomitant CRT, radiotherapy method, total radi-
ation dose, and radiation field laterality); laboratory
test results (neutrophil and lymphocyte counts, and
concentrations of albumin, hemoglobin, urea nitro-
gen and creatinine immediately before radiotherapy);
and completion of radiotherapy. ECOG PS score [13]
was as follows: score 0, fully active, able to carry on
all pre-disease performance without restriction.;
score 1, restricted in physically strenuous activity but
ambulatory and able to carry out work of a light or
sedentary nature, e.g., light housework, office work.;
score 2, ambulatory and capable of all selfcare but
unable to carry out any work activities. Up and
about more than 50% of waking hours.; score 3, cap-
able of only limited selfcare, confined to bed or chair
more than 50% of waking hours; and score 4, com-
pletely disabled. Cannot carry on any selfcare. To-
tally confined to bed or chair. The NLR was
calculated by dividing the neutrophil count by the
lymphocyte count. A cut-off value of 5 was used to
categorize patients with high (NLR > 5) or low
(NLR < 5) systemic inflammation. This cut-off value
was chosen based on a systematic review of the NLR
literature on cancer, showing NLR > 5 as a predictive
marker of cancer outcomes in over 30 studies of
15,500 cancer patients [14].
Concomitant chemotherapy was categorized as none
(radiotherapy alone), cetuximab (bioradiotherapy [BRT]),
and cisplatin or carboplatin CRT. The radiotherapy
method was categorized as three-dimensional conformal
radiotherapy (3D-CRT) or intensity-modulated radiother-
apy (IMRT). Radiation field laterality was categorized as
unilateral or bilateral. Completion of radiotherapy was cat-
egorized into three groups: completion, discontinuation,
and treatment pause.
Statistical analysis
The primary objective of this study was to determine
whether NLR is associated with grade 3 mucositis. Pa-
tient characteristics were assessed for differences in
radiation-induced mucositis severity (grade 1 or 2 vs.
grade 3). The exploratory variables analyzed in the uni-
variate logistic regression model were included in the
multivariate logistic regression model and assessed as
follows: age; BMI; pack-years of smoking; NLR; and con-
centrations of albumin, hemoglobin, urea nitrogen and
creatinine (continuous for univariate analysis to assess
linear trends); sex (male vs. female); diabetes mellitus
(with vs. without); EOCG PS (0,1 vs. 2, 3); primary
tumor location (hypopharynx vs. larynx); stage (I or II
vs. III or IV); concomitant CRT (radiotherapy alone vs.
BRT or CRT); and radiotherapy method (3D-CRT vs.
IMRT). Baseline variables with p < 0.20 in the univariate
analysis were included in the multivariable models.
The cumulative incidence of grade 3 mucositis in the
two groups (NLR > 5 vs. NLR < 5) was estimated using the
Kaplan–Meier method, and grade 3 mucositis estimates
were compared using the log-rank test. Patients with
grade 3 mucositis were calculated from the start of radio-
therapy to the date of the event. Patients without grade 3
mucositis during radiotherapy were censored at the end of
radiotherapy for cumulative incidence analysis.
All statistical analyses were performed using Statistical
Package for the Social Sciences for Windows (version
25; IBM Corp., Tokyo, Japan). Statistical significance was
defined as a two-sided p-value < 0.05.
Results
Patient demographics for the total population
A total of 99 patients were included in this retrospective
study. Table 1 outlines their characteristics. Grade 3
radiation-induced mucositis occurred in 39 patients
(39%). None of the patients developed grade 4 or 5 mu-
cositis. All the patients received oral care because a part
of their oral cavities was included in the radiation field.
Association of NLR with grade 3 mucositis
Table 2 provides the results of the univariate analysis.
The following two variables were found to be signifi-
cantly associated with the occurrence of grade 3 mucosi-
tis: NLR (OR = 1.09; 95% CI = 1.02–1.16; p = 0.016) and
smoking (OR = 1.02; 95% CI = 1.00–1.03; p = 0.048). Ra-
diation field laterality was not analyzed in the logistic
regression model because only two patients received
radiotherapy unilaterally.
Table 3 presents multivariate analysis results. NLR
was significantly associated with grade 3 mucositis
(OR = 1.09; 95% CI = 1.01–1.17; p = 0.021). Moreover,
Kaplan–Meier curves showed that patients with
NLR > 5 were significantly associated with the
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development of grade 3 mucositis (p = 0.045) (Fig. 1).
Smoking was no longer associated with grade 3 mu-
cositis, as adjusted by other variables.
Discussion
This study investigated the outcomes for grade 3 muco-
sitis during radiotherapy for hypopharyngeal or laryngeal
Table 1 Patient characteristics
Radiotherapy-induced mucositis
Grade 1&2 Grade 3
N = 60 N = 39
Characteristic Category N % N %
Sex Male 56 93 36 92
Female 4 7 3 8
Age Median (25–75% tile) 65.0 (59.5–72.0) 66.0 (63.0–71.5)
BMI (kg/m2) Median (25–75% tile) 21.6 (18.7–24.0) 21.1 (19.3–24.3)
Smoking (pack-years) Median (25–75% tile) 29.6 (15.0–42.9) 40.0 (17.5–63.8)
EOCG PS 0 27 45 21 54
1 25 42 17 44
2 6 10 1 3
3 2 3 0 0
Diabetes mellitus Without 47 78 32 82
With 13 22 7 18
Primary tumor location Hypopharynx 52 87 33 85
Larynx 8 22 6 15
Stage 1 3 5 0 0
2 7 12 6 15
3 11 18 9 23
4 39 65 24 62
Concomitant chemoradiotherapy Radiotherapy alone 9 15 2 5
BRT 11 18 3 8
CRT 40 67 34 87
Total radiation dose (Gy) Median (25–75% tile) 70.0 (63.0–70.0) 70.0 (66.0–70.0)
Radiotherapy method IMRT 24 40 19 49
3D-CRT 36 60 20 51
Radiation field laterality Bilateral 59 98 38 97
Lateral 1 2 1 3
Completion of radiotherapy Completion 55 92 35 90
Discontinuation 3 5 2 5
Treatment pause 2 3 2 5
NLR Median (25–75% tile) 2.6 (2.0–4.7) 4.2 (2.1–11.5)
NLR < 5 46 77 23 59
NLR > 5 14 23 16 41
albumin (g/dL) Median (25–75% tile) 3.7 (3.5–4.2) 3.8 (3.5–4.1)
Hemoglobin (mg/dL) Median (25–75% tile) 13.1 (11.9–14.1) 13.3 (11.6–14.4)
Urea nitrogen (mg/dL) Median (25–75% tile) 13 (11–17) 14 (12–19)
Creatinine (mg/dL) Median (25–75% tile) 0.76 (0.67–0.92) 0.78 (0.68–0.92)
Abbreviations: BMI Body mass index, EOCG PS Eastern Cooperative Oncology Group performance status, NLR Neutrophil-to-lymphocyte ratio, BRT Bioradiotherapy
(cetuximab with radiotherapy), CRT Chemotherapy (cisplatin or carboplatin with radiotherapy), IMRT Intensity-modulated radiotherapy, and 3D-CRT Three-
dimensional conformal radiotherapy
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cancer with adjustment for clinical characteristics. We
selected hypopharyngeal or laryngeal cancer patients be-
cause radiotherapy-induced hypopharyngeal or laryngeal
mucositis was not affected by teeth [12] or xerostomia
[15], which were thought to have led to severe mucositis
in oral or oropharyngeal cancer patients.
The results showed that the development of grade
3 mucositis was significantly associated with the
NLR. Moreover, patients with a higher NLR (NLR >
5) prior to radiotherapy were significantly associated
with the incidence of grade 3 mucositis during
radiotherapy.
Elevated NLR was associated with decreased antitumor
activity [16], tumor progression, and metastasis [8].
These results imply that tumor development may be re-
lated to the NLR imbalance in cancer patients. The NLR
has been reported to be a strong predictor of mortality
in patients with head and neck, esophageal, lung, breast,
gastric, pancreatic, colorectal, bladder, and ovarian can-
cers [9, 10, 17–24]. In this study, survival analysis was
not performed because the aim of our study was not sur-
vival results.
The main novel result of our study is that a higher
NLR is associated with grade 3 radiation-induced muco-
sitis. This result may be biologically plausible because
neutrophils and lymphocytes are involved in the inflam-
matory system. In response to radiation-induced muco-
sal injury, a multifactorial network of chemical signals
initiates and maintains a host response designed to
“heal” the afflicted tissue [25]. This involves activation
and directed migration of leukocytes (neutrophils,
monocytes, and eosinophils), mast cells, and lympho-
cytes from the venous system to damage sites [8]. In
head and neck squamous cell carcinoma, cancer-related
inflammation is characterized by increased circulating
concentrations of pro-inflammatory cytokines and C-
reactive protein [9], which enhance the recruitment of
circulating neutrophils, while also inhibiting the recruit-
ment of lymphocytes for circulation [26]. These changes
lead to the development of cancer-related syndromes
Table 2 Univariate analysis for grade 3 mucositis in patients receiving radiotherapy for pharyngeal or laryngeal cancer
Variable Category (Reference) OR 95% CI p-value
Sex Male (Female) 0.86 0.18 – 4.06 0.846
Age 1.00 0.96 – 1.05 0.894
BMI (kg/m2) 1.04 0.93 – 1.16 0.521
Smoking (pack-years) 1.02 1.00 – 1.03 0.048
EOCG PS > 2 (0 or 1) 0.17 0.02 – 1.43 0.103
Diabetes mellitus With (Without) 0.79 0.28 – 2.20 0.653
Primary tumor location Hypopharynx (Larynx) 1.18 0.38 – 3.71 0.775
Stage III, IV (I, II) 1.10 0.37 – 3.32 0.866
Therapy BRT or CRT (Radiotherapy alone) 3.27 0.67 – 16.00 0.145
Radiotherapy method IMRT (3D-CRT) 1.43 0.63 – 3.21 0.393
NLR 1.09 1.02 – 1.16 0.016
Concentration of albumin 1.42 0.62 – 3.24 0.404
Concentration of hemoglobin 1.07 0.84 – 1.35 0.593
Concentration of urea nitrogen 1.03 0.97 – 1.09 0.390
Concentration of creatinine 0.97 0.26 – 3.56 0.959
Abbreviations: BMI Body mass index, EOCG PS Eastern Cooperative Oncology Group performance status, NLR Neutrophil-to-lymphocyte ratio, BRT Bioradiotherapy
(cetuximab with radiotherapy), CRT Chemotherapy (cisplatin or carboplatin with radiotherapy), IMRT Intensity-modulated radiotherapy, 3D-CRT Three-dimensional
conformal radiotherapy, OR Odds ratio, and CI Confidence interval
Table 3 Multivariate logistic regression analysis for grade 3 mucositis in patients receiving radiotherapy for pharyngeal or laryngeal
cancer
Variable Category (Reference) OR 95% CI p-value
NLR 1.09 1.01 – 1.17 0.021
Smoking (pack-years) 1.01 1.00 – 1.03 0.133
Therapy BRT or CRT (Radiotherapy alone) 3.29 0.58 – 19.64 0.179
EOCG PS > 2 (0 or 1) 0.27 0.03 – 2.37 0.238
Abbreviations: NLR Neutrophil-to-lymphocyte ratio, EOCG PS Eastern Cooperative Oncology Group performance status, BRT Bioradiotherapy (cetuximab with
radiotherapy), CRT Chemotherapy (cisplatin or carboplatin with radiotherapy), OR Odds ratio, and CI Confidence interval
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including fever, night sweats, fatigue, cachexia, and bone
and muscle pain [27]. Therefore, a higher NLR may in-
duce severe mucositis during radiotherapy.
Evaluating NLR on the pre-radiotherapy stage may
be useful to decide to conduct percutaneous endo-
scopic gastrostomy (PEG) before CRT. We showed
that aspiration pneumonia during radiotherapy was
associated with hypopharyngeal cancer, severe oral
mucositis, and nasogastric tube feeding in the retro-
spective study. Moreover, the development of aspir-
ation pneumonia was one of the reasons for the
discontinuation of radiotherapy [5]. NCCN Guidelines
Version 3.2021 [6] shows that all patients should be
evaluated for nutritional risks and receive nutrition
counseling by a registered dietitian and/or indicated
treatment with various nutrition interventions, such
as feeding tubes. However, criteria for prophylactic
placement of PEG tubes before head and neck cancer
treatment have not been established. If we can detect
higher NLR on the pre-radiotherapy stage, we can
conduct PEG before treatment, and aspiration pneu-
monia can be prevented during radiotherapy.
There are some limitations to this study. First, this is a
single-center retrospective study with a small number of
patients; therefore, it is unclear whether the results ob-
tained can be generalized. Second, data on QOL evalu-
ation could not be obtained because of the retrospective
design of the study. However, the main strength of our
study is that the study population was most likely homo-
geneous because the patients underwent definitive radio-
therapy or CRT for hypopharyngeal or laryngeal cancer.
Moreover, all patients received the same oral care man-
agement during radiotherapy because a part of their oral
cavities was included in the radiation field. We would
like to conduct a prospective study with a large sample
size and examine QOL evaluation, such as the European
Organization for Research and Treatment of Cancer
QLQ-C30 or oral mucositis-specific surveys, in the
future.
Conclusions
The findings of this study suggest that a higher NLR was
a risk factor for severe mucositis in patients who
undergo definitive radiotherapy or CRT for hypopharyn-
geal or laryngeal cancer.
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